GoodRx Holdings (GDRX) Shares Outstanding (Weighted Average) (2019 - 2026)
GoodRx Holdings' Shares Outstanding (Weighted Average) history spans 7 years, with the latest figure at $356.3 million for Q4 2025.
- On a quarterly basis, Shares Outstanding (Weighted Average) fell 7.62% to $356.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $356.3 million, a 7.62% decrease, with the full-year FY2025 number at $356.3 million, down 7.62% from a year prior.
- Shares Outstanding (Weighted Average) hit $356.3 million in Q4 2025 for GoodRx Holdings, down from $360.7 million in the prior quarter.
- Over the last five years, Shares Outstanding (Weighted Average) for GDRX hit a ceiling of $414.7 million in Q1 2022 and a floor of $356.3 million in Q4 2025.
- Historically, Shares Outstanding (Weighted Average) has averaged $396.4 million across 5 years, with a median of $408.5 million in 2021.
- Biggest five-year swings in Shares Outstanding (Weighted Average): surged 77.53% in 2021 and later fell 8.0% in 2024.
- Tracing GDRX's Shares Outstanding (Weighted Average) over 5 years: stood at $410.0 million in 2021, then increased by 0.7% to $412.9 million in 2022, then fell by 0.62% to $410.3 million in 2023, then decreased by 5.99% to $385.7 million in 2024, then fell by 7.62% to $356.3 million in 2025.
- Business Quant data shows Shares Outstanding (Weighted Average) for GDRX at $356.3 million in Q4 2025, $360.7 million in Q3 2025, and $356.6 million in Q2 2025.